At the end of the trial, compared to the group taking sulfonylureas, participants who consistently took GLP-1 medications for the entire three-year period of the study had the most pronounced reduction in risk 18%, or roughly 4 fewer major cardiovascular events per 100 people over three years
The secondary outcomes included comparing the proportion and duration of time spent in the target range at 24 and 52 weeks
By stabilizing the mucus layer, reinforcing tight junctions, and participating in SCFA cross-feeding networks , Akkermansia contributes to enteroendocrine signaling environments that influence appetite regulation and metabolic flexibility
It is FDA-approved for weight loss in non-diabetic individuals and is typically administered as a daily injection
Glutathione Synthesis in Cancer Cells
Medicaid Coverage of and Spending on GLP-1s